Coronavirus 2019-2020 thread (no unsubstantiated rumours!)


B.I.B.

Captain
Yes, I agree with you on the potential logistic nightmare. I believe I was the first here to bring up the potential "logistic issues" with the Pfizer vaccine when their initial glowing report came out. It is a huge issue. In fact, I was just chatting with a colleague of mine in the hallway and I told him that I would choose the Moderna vaccine over the Pfizer vaccine, if I have a choice, because of the high risk of potentially messing up the ideal temperature during transit and storage.

By the way, the Moderna vaccine is stable at -20 deg C, which is the typical temperature of our kitchen freezer. So handling the Moderna vaccine is a lot easier than the Pfizer one. Transporting samples that must be kept at -20 is easy. And storing them is also a lot easier since every facility should be some kind of a kitchen freezer.

Please, Log in or Register to view URLs content!

I'm not sure about calling it a "criminal manner"... Every company has its right to advertise their products. As long as they faithfully and accurately report their findings, they are ok. If they manipulate their data, then it's criminal. It's up to the government to evaluate each claim unbiased and comes up with a decision.

Should there be any concern that they might have taken short cuts in the rush to come out with a vaccine?
 

vesicles

Colonel
Should there be any concern that they might have taken short cuts in the rush to come out with a vaccine?

Yes, I am concerned. That's why I suggest we should wait for a few months before we take the injection. Hopefully nothing serious happens and we can all take it and forget all about it. Mishaps with vaccines have been known to happen all the time. And that's when companies spend years working on a vaccine and under the most strict regulations. Now every precaution has been thrown out the window... As I've said before, I am very uncomfortable with the speed of developing all these vaccines. It's just too fast. I'm almost 100% sure, not a few, but many shortcuts have been made... Everyone is desperate and everyone wants this thing to end. I myself am frustrated and want this thing to be over with ASAP. A part of me wants to take the vaccine at this very moment so that I don't have to deal with all the frustrations and mess... I sincerely hope these vaccines work as intended, with no serious side effects...
 
Last edited:

KYli

Captain
I think Pfizer and Moderna are much more promising. For developing countries, China is the best bet now.
Please, Log in or Register to view URLs content!

The dose of AstraZeneca Plc’s Covid vaccine that showed the highest level of effectiveness was tested in a younger population than a bigger dose that showed less efficacy, according to the head of the U.S. Operation Warp Speed program.

The vaccine being developed with Oxford University was 90 per cent effective when a half-dose was given before a full-dose booster, the partners said on Monday. However, that regime was administered to participants in a group whose age was capped at 55, Warp Speed’s Moncef Slaoui said Tuesday in a phone call with reporters.

Researchers have been puzzling about the AstraZeneca report since it was released, wondering why a smaller dose of the vaccine might have appeared to be more effective. Most of the people in the trial received two full doses or a placebo. The regimen of two full doses regimen was 62 per cent effective. That group included people who were older than 55, Slaoui said.

AstraZeneca reiterated that the data will be published in a peer-reviewed journal in due course.

There was no age breakdown given for the two groups from AstraZeneca when the company reported its results on Monday. The initial half-dose was used in some people because of an error in the quantity of vaccine put into some vials, Slaoui said.

“There are a number of variables that we need to understand, and what has been the role of each one of them in achieving the difference in efficacy,” Slaoui said.
 

Intrepid

Captain
How long have the Russians been vaccinating and can one recognize the vaccination campaign in the development of the number of infections and victims?
 

AndrewS

Major
Registered Member
Yes, I agree with you on the potential logistic nightmare. I believe I was the first here to bring up the potential "logistic issues" with the Pfizer vaccine when their initial glowing report came out. It is a huge issue. In fact, I was just chatting with a colleague of mine in the hallway and I told him that I would choose the Moderna vaccine over the Pfizer vaccine, if I have a choice, because of the high risk of potentially messing up the ideal temperature during transit and storage.

I actually brought up the logistical issue of -80C before, some months ago.

Please, Log in or Register to view URLs content!

I'm not sure about calling it a "criminal manner"... Every company has its right to advertise their products. As long as they faithfully and accurately report their findings, they are ok. If they manipulate their data, then it's criminal. It's up to the government to evaluate each claim unbiased and comes up with a decision.

You're taking a narrow pharma view of the situation.

Pfizer/Modern are publicising their vaccines which are actually behind other vaccines in gaining approval, and they know it.
And they have to know that a larger uptake of their vaccines will result in more deaths.

But legally, they will get away with this, which is why I said "almost a criminal manner".

And actually, only the USA and New Zealand allow pharmaceutical companies to advertise their products.

Every other country in the world has banned this, because they know the general public is easily misled.
Because the public can influence their governments or doctors to buy those products.
 

KYli

Captain
Look like Sinopharm would be the first Chinese vaccine to gain regulatory approval. However, it hasn't release the efficacy rate yet.
Please, Log in or Register to view URLs content!

China Covid-19 vaccine maker seeks approval for public use

BEIJING (BLOOMBERG) - A leading Chinese vaccine developer has applied for authorisation to bring its Covid-19 vaccine to the market, seeking to get a jump on Western rivals as the race for a working shot against the pandemic enters the final stretch.

China National Biotec Group Co. has submitted an application to Chinese regulators, reported state media Xinhua Finance on Wednesday (Nov 25), citing parent company Sinopharm's vice general manager Shi Shengyi.

The application likely includes data from the company's Phase III human testing conducted in the Middle East and South America.

Stocks related to Sinopharm Group, including its Hong Kong unit, surged on Wednesday after the news.

A CNBG spokeswoman said she had no further information when contacted by Bloomberg. Calls to Sinopharm Group went unanswered.

With the application, CNBG will likely become the first developer outside of Russia to see its shots made available for general public use, underscoring China's determination to be a major player in supplying inoculations to countries around the world.

Western drugmakers like Pfizer Inc. are only at the stage of seeking authorisation for emergency use of their shots, a status China granted to its developers months ago.

The race has taken on vital importance as countries look to more definitively re-open their economies and stem a pandemic that has sickened more than 59 million.

Working vaccines are seen as the best hope as a fresh wave of infections is forcing nations to reintroduce lockdowns and other restrictions.

A state-owned drugmaker that has a dominant share of China's vaccine market, CNBG in April was among the world's first to push experimental shots to the crucial final stage of human testing. The company's research institutes developed two shots using an inactivated version of the virus to stimulate immune response, an approach widely adopted by many of the existing vaccines used around the world.

Despite the fact that the vaccines haven't yet received regulatory approval for widespread use, they have already been given to hundreds of thousands of people in China under an emergency-use program. That has raised concern among scientists of potential risks in using shots whose safety has yet to be thoroughly studied.

CNBG has said that its phase III trials - involving more than 50,000 people in countries from Argentina to Egypt - have been progressing smoothly, and it has not received any reports of serious adverse events.

Safety has become a major concern as drugmakers compress the vaccine development process from years to a matter of months.

AstraZeneca Plc and Johnson & Johnson paused their trials after a participant developed an unexplained illness. Another Chinese frontrunner, Sinovac Biotech Ltd., also saw its trial briefly halted in Brazil after a participant died.

All three trials resumed after investigators found no evidence that the events were caused by the vaccines.

Pfizer said this month that the shot it co-developed with BioNTech has a protection rate of more than 90 per cent. Russia later declared that its Sputnik V vaccine has achieved a protection rate of 92 per cent. CNBG has not released any public data on the efficacy of its shots.
 

localizer

Colonel
Registered Member
Look like Sinopharm would be the first Chinese vaccine to gain regulatory approval. However, it hasn't release the efficacy rate yet.
Please, Log in or Register to view URLs content!

China Covid-19 vaccine maker seeks approval for public use

BEIJING (BLOOMBERG) - A leading Chinese vaccine developer has applied for authorisation to bring its Covid-19 vaccine to the market, seeking to get a jump on Western rivals as the race for a working shot against the pandemic enters the final stretch.

China National Biotec Group Co. has submitted an application to Chinese regulators, reported state media Xinhua Finance on Wednesday (Nov 25), citing parent company Sinopharm's vice general manager Shi Shengyi.

The application likely includes data from the company's Phase III human testing conducted in the Middle East and South America.

Stocks related to Sinopharm Group, including its Hong Kong unit, surged on Wednesday after the news.

A CNBG spokeswoman said she had no further information when contacted by Bloomberg. Calls to Sinopharm Group went unanswered.

With the application, CNBG will likely become the first developer outside of Russia to see its shots made available for general public use, underscoring China's determination to be a major player in supplying inoculations to countries around the world.

Western drugmakers like Pfizer Inc. are only at the stage of seeking authorisation for emergency use of their shots, a status China granted to its developers months ago.

The race has taken on vital importance as countries look to more definitively re-open their economies and stem a pandemic that has sickened more than 59 million.

Working vaccines are seen as the best hope as a fresh wave of infections is forcing nations to reintroduce lockdowns and other restrictions.

A state-owned drugmaker that has a dominant share of China's vaccine market, CNBG in April was among the world's first to push experimental shots to the crucial final stage of human testing. The company's research institutes developed two shots using an inactivated version of the virus to stimulate immune response, an approach widely adopted by many of the existing vaccines used around the world.

Despite the fact that the vaccines haven't yet received regulatory approval for widespread use, they have already been given to hundreds of thousands of people in China under an emergency-use program. That has raised concern among scientists of potential risks in using shots whose safety has yet to be thoroughly studied.

CNBG has said that its phase III trials - involving more than 50,000 people in countries from Argentina to Egypt - have been progressing smoothly, and it has not received any reports of serious adverse events.

Safety has become a major concern as drugmakers compress the vaccine development process from years to a matter of months.

AstraZeneca Plc and Johnson & Johnson paused their trials after a participant developed an unexplained illness. Another Chinese frontrunner, Sinovac Biotech Ltd., also saw its trial briefly halted in Brazil after a participant died.

All three trials resumed after investigators found no evidence that the events were caused by the vaccines.

Pfizer said this month that the shot it co-developed with BioNTech has a protection rate of more than 90 per cent. Russia later declared that its Sputnik V vaccine has achieved a protection rate of 92 per cent. CNBG has not released any public data on the efficacy of its shots.


No worries, US developed its drugs with $6 trillion of stimulus and over a quarter million dead.
Please, Log in or Register to view URLs content!
The vaccine market isn't worth trillions. Nor our loved ones.

Also, China can beat the US in distribution, especially to non-OECD.
 

Attachments

  • 1606281883536.png
    1606281883536.png
    20.1 KB · Views: 0
Last edited:

LesAdieux

Junior Member
at the moment, there're only 300+ active cases in China, with a dozen or so new cases reported daily. there's no point to vaccinate 1.4 billion people for that. the vaccines will be used abroad, they need local authorization from each country.
 

Top